Privia Health Group, Inc. (PRVA)
NASDAQ: PRVA · Real-Time Price · USD
23.42
+0.56 (2.45%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Privia Health Group Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Privia Health Group stock have an average target of 27.19, with a low estimate of 20 and a high estimate of 40. The average target predicts an increase of 16.10% from the current stock price of 23.42.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Privia Health Group stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 6 | 6 | 6 | 6 |
Buy | 7 | 7 | 8 | 10 | 9 | 9 |
Hold | 2 | 2 | 2 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 13 | 16 | 17 | 16 | 16 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Baird | Baird | Buy Maintains $24 → $26 | Buy | Maintains | $24 → $26 | +11.02% | Apr 15, 2025 |
Barclays | Barclays | Hold Maintains $21 → $23 | Hold | Maintains | $21 → $23 | -1.79% | Apr 10, 2025 |
Truist Securities | Truist Securities | Strong Buy Maintains $27 → $28 | Strong Buy | Maintains | $27 → $28 | +19.56% | Apr 10, 2025 |
Needham | Needham | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +28.10% | Apr 10, 2025 |
Needham | Needham | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +28.10% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
3.28B
from 1.74B
Increased by 88.96%
Revenue Next Year
3.63B
from 3.28B
Increased by 10.70%
EPS This Year
0.25
from 0.11
Increased by 129.34%
EPS Next Year
0.38
from 0.25
Increased by 51.13%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 3.4B | 3.9B | 4.5B | ||
Avg | 3.3B | 3.6B | 4.0B | ||
Low | 3.1B | 3.4B | 3.7B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 96.2% | 17.8% | 23.7% | ||
Avg | 89.0% | 10.7% | 11.5% | ||
Low | 79.7% | 4.1% | 1.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.39 | 0.84 | 0.64 |
Avg | 0.25 | 0.38 | 0.47 |
Low | 0.18 | 0.27 | 0.39 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 253.2% | 233.0% | 68.0% |
Avg | 129.3% | 51.1% | 22.6% |
Low | 60.4% | 8.8% | 2.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.